

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- | | |
|-----|-----------|
| n/a | Confirmed |
|-----|-----------|
- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
 - A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
 - The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
 - A description of all covariates tested
 - A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
 - A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
 - For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
 - For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
 - For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
 - Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection SoftMax Pro 7.0.3, the movies stacks was automatically collected using the SerialEM 3.7, MODELLER version 9.4 for modeling of missing protein loops, UCSF Chimera version 1.12 for preparation of the receptor, AMBER Tools version 18 # for assignment of ligand parameters + coordinate/topology file generation, GROMACS 2018.4 patched with PLUMED 2.5.0 for performing metadynamics simulations.

Data analysis GraphPad Prism 7 and 8, FlowJo 10.7, CryoSPARC 3.2.1, Relion 3.0, MotionCor2 1.4.0, GCTF 1.18, JSPR, PYEM 2.0.0, UCSF Chimera 1.12, Coot 0.9.2, Phenix 1.18.2, MolProbity 4.2, PyMOL 2.1, Molaris-XG 9.15 and PLUMED version 2.5.0 for reconstruction of the FES and error estimation (using block analysis according to the "Master ISDD tutorial 2020: Metadynamics simulations with PLUMED"), GROMACS 2018.4 patched with PLUMED 2.5.0 for analysis of the trajectories, Matplotlib version 3.4.3 # for creating the FES plots including error estimates.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

All data generated or analyzed during this study are included in this article and its Supplementary Information. Calculated inactive receptor models (obtained by metadynamics simulations) are provided as supplementary PDB files. The 3D Cryo-EM density maps of the 2-PCCA-bound and apo GPR88-Gi-scFv16 complex have

been deposited in the Electron Microscopy Data Bank database under accession codes EMD-31164 and EMD-32904, respectively. The atomic coordinates for the atomic models of the 2-PCCA-GPR88-Gi-scFv16 complexes generated in this study have been deposited in the Protein Data Bank database under accession codes 7EJX and 7WZ4, respectively. The raw data for the main Fig. 1b, 1c, 2h-j, 4 and Supplementary Fig. 1b, 1c, 4, 5e, 7, 8b-e, 10 generated in this study are provided in the Source Data file. The structural models of rhodopsin-Gi1, μ OR-Gi1, α 2BAR-Gi1 and A1R-Gi2 used in this study are available in the Protein Data Bank database under accession codes 6CMO, 6DDE, 6K42 and 6D9H, respectively. Source data are provided with this paper.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

Data exclusions

Replication

Randomization

Blinding

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a | Involved in the study

Antibodies

Eukaryotic cell lines

Palaeontology and archaeology

Animals and other organisms

Human research participants

Clinical data

Dual use research of concern

Methods

n/a | Involved in the study

ChIP-seq

Flow cytometry

MRI-based neuroimaging

Antibodies

Antibodies used

Validation

Eukaryotic cell lines

Policy information about [cell lines](#)

Cell line source(s)

Authentication

Mycoplasma contamination

Mycoplasma contamination	detection kit (Lonza).
Commonly misidentified lines (See ICLAC register)	None used.

Flow Cytometry

Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation	HEK293 cells transiently expressing a test FLAG-GPR88 construct along with the NanoBiT-Gi1 sensor were labeled with the anti-DYKDDDDK tag, followed by the Alexa Fluor 488-conjugated anti-mouse IgG secondary antibody.
Instrument	EC800 flow cytometer (Sony)
Software	FlowJo software (FlowJo)
Cell population abundance	N/A. Cell population abundance analysis is not needed in this study.
Gating strategy	N/A. We used all of the recorded fluorescent signals and calculated a simple mean value. Therefore, description of gating strategy or the plot representation was not performed.

- Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.